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Abstract 
Hypertrophic cardiomyopathy (HCM) is the most common inherited human heart disease. 
The same disease has a high prevalence in cats, where it is also suspected to be inherited. 
More than 1500 variants in MYBPC3, MYH7 and other sarcomeric genes are associated with 
human HCM, while in cats, only two causative variants in MYBPC3 are currently known. 
Here, we describe an adult Domestic Shorthair cat with arterial thrombo-embolism and heart 
failure that was diagnosed with HCM on necropsy. Sequencing of the coding regions of 
MYBPC3 and MYH7 revealed 21 variants, of which the MYH7 c.5647G>A (p. (Glu1883Lys)) 
variant was further analysed, because its orthologous variant had already been reported in a 
human patient with HCM, but with limited causal evidence. This variant affects the highly 
conserved assembly competence domain, is predicted in silico to be damaging and was found 
only once in population databases. Recently, functional studies have confirmed its predicted 
damaging effect and a paralogous variant in MYH6 has been associated with cardiac disease 
in humans as well. This report of an orthologous variant in a cat with HCM and its absence in 
200 additional cats provides further evidence for its disease-causing nature. As the first report 
of feline HCM caused by a variant in MYH7, this study also emphasizes this gene as a 
candidate gene for future studies in cats and highlights the similarity between human and 
feline HCM. 
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Introduction 
Hypertrophic cardiomyopathy (HCM; Phenotype MIM number: 192600) is the most common 
inherited human heart disease, affecting at least 1 in 500 people.1 It is characterized by 
concentric hypertrophy of the left ventricle that cannot be attributed to secondary causes.2 The 
clinical expression is widely variable, ranging from longevity without symptoms to 
congestive heart failure or sudden death.2 More than 1500 variants are associated with human 
HCM, most of them limited to a single patient family.3 They mainly reside in sarcomeric 
genes, of which MYBPC3 and MYH7 are the most important, containing 70% of the variants.1 
MYBPC3 (human geneID: 4607) consists of 33 exons and encodes the cardiac myosin binding 
protein C of 1274 amino acids. The protein seems to play a key role in the regulation of 
sarcomeric contractility and may also influence sarcomere structure.4,5 Known causative 
variants in MYBPC3 are either missense or truncating variants.6 MYH7 (human geneID: 4625) 
comprises 40 exons and encodes myosin-7 of 1935 amino acids, the dominant myosin heavy 
chain protein in cardiac and type I skeletal muscle fibres.7,8 This protein generates contractile 
force through hydrolisation of ATP and interactions with actin at the N-terminal head and 
channels this force through its C-terminal tail to the cytoskeleton.8 HCM-causing variants in 
MYH7 are principally missense variants.6  Missense variants in MYH7 have also been 
associated with dilated cardiomyopathy, left ventricular non-compaction and skeletal muscle 
diseases.2,9 One such skeletal muscle disease is myosin storage myopathy (MSM), 
characterized by slowly progressive muscle weakness and hyaline bodies in type I muscle 
fibres, that is caused by variants in exons 37-40 (exons are numbered like in NG_007884.1).9  
HCM (OMIA 000515-9685) is the most common heart disease in cats, affecting almost 15% 
of the feline population.10 HCM is often associated with certain breeds, for example the 
Maine Coon, Ragdoll and British Shorthair breeds.11 Nevertheless, most patients are non-
pedigree Domestic Shorthairs.12 Feline HCM is considered the best spontaneous animal 
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model for human HCM for its similarity in morphology, histopathology and clinical 
course.13,14 A genetic aetiology is suspected in several breeds as well as in Domestic 
Shorthairs.12 However, only two causative variants in cats have yet been identified in 
MYBPC3, XM_019812396.1:c.91G>C in Maine Coons15 and c.2455C>T in Ragdolls.11 An 
orthologue of the latter variant also causes HCM in humans.16 
The aim of this study was to identify the causative variant in cats affected with HCM. Based 
on the hypothesis that human and feline HCM have a similar genetic cause, we sequenced the 
coding regions of MYBPC3 (geneID: 101094698) and MYH7 (geneID: 101096736). In this 
report, we describe the case in which a causal variant was identified. The results from eight 
other cases that were sequenced, but where no causal variant was found, are described in 
Supplementary Table 6. 
 
Materials and methods 
Clinical examination 
A male castrated Domestic Shorthair, estimated to be six years old, was presented to the 
emergency department of Ghent University’s small animal clinic for acute paraplegia, pain 
and severe dyspnoea with cyanosis. A physical examination and thoracic and cardiac focused 
assessment sonography scan were performed.17 Due to the severe clinical signs and poor 
prognosis, the cat was euthanized. 
Pathological examination 
A complete necropsy was performed, including examination and weighing of the heart, and 
the heart was frozen at -80°C thereafter. A transverse slice of frozen ventricular tissue was 
fixated in 4% buffered formaldehyde, paraffin embedded and routinely processed for 
histopathological examination. Five μm sections were stained with haematoxylin-eosin, Von 
Giesson, Masson’s Trichrome, Prussian blue and Alcian Blue (pH 2.5). Immunohistochemical 
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stainings included elastin (Novocastra lyophilized monoclonal mouse antibody elastin, Cat 
No. NCL-ELASTIN, Leica biosystems, Newcastle, United Kingdom) and smooth muscle 
actin (monoclonal mouse anti-human smooth muscle actin clone 1A4, Cat No. M085101-2, 
Dako, Glostrup, Denmark). 
Genetic analysis 
Genomic DNA was isolated from 100 mg frozen heart tissue from the case by proteinase K 
digestion and subsequent phenol/chloroform extraction and ethanol precipitation.18 The purity 
and quantity of the DNA were determined with the NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). The gDNA was first tested for the two 
known feline HCM-causing MYBPC3 c.91G>C and c.2455C>T variants using an in-house 
developed probe-based qPCR assay. 
Total RNA was isolated from 100 mg frozen heart tissue from the case using the Aurum Total 
RNA Fatty and Fibrous Tissue Kit, including an on-column DNase digest (Bio-Rad 
Laboratories, Hercules, CA, USA). The purity and quantity of the RNA were determined with 
the NanoDrop ND-1000 spectrophotometer, the integrity was assessed by evaluating the 
28S/18S rRNA bands on agarose gel and possible DNA contamination was detected with 
minus-RT-PCR using an in-house developed UBC integrity assay.19 Reverse transcription was 
performed on 1 μg high-quality, DNA-free RNA using the ImProm-II Reverse Transcription 
System (Promega Corporation, Madison, WI, USA) with oligo(dT) and random hexamer 
primers. Complementary DNA was 10 times diluted with water and 2 μl was used as a 
template for PCR. The integrity and amplificability of the cDNA were tested with the UBC 
integrity assay. 
Primer pairs were designed to generate amplicons covering the complete coding regions of 
MYBPC3 (Acc. No.: XM_019812396.1) and MYH7 (Acc. No.: XM_006932746.4) on cDNA 
using the NCBI Primer-BLAST software20, checking for primer specificity and avoiding 
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known SNPs. Regions that form secondary structures, as predicted by Mfold21, were excluded 
as primer binding site. PCR was performed with Tempase Hot Start polymerase (VWR 
International, Leuven, Belgium) and amplicons were analysed via agarose gel electrophoresis. 
Sequencing reactions were performed with the BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Foster City, CA, USA) with individual PCR primers as sequencing 
primers. The sequences were run at Eurofins Genomics (Ebersberg, Germany) and the results 
were analysed with BioEdit v7.2.5.22 For missense variants, the evolutionary conservation of 
the affected amino acid was checked via ClustalW and quantified with the ConSurf web tool23 
and the functional effect of the substitution was predicted in silico with PROVEAN24 and 
PolyPhen-2.25 The Exome Variant Server (EVS)26, Exome Aggregation Consortium (ExAC)27 
and Genome Aggregation Database (GnomAD)27 databases were searched for orthologous 
variants in humans. 
A BseRI PCR-RFLP assay was developed to genotype exon 38 of MYH7 (Acc. No.: 
NC_018728.3; exon 38 spans positions 76166287 to 76166382) for the c.5647G>A 
(p.(Glu1883Lys)) variant on gDNA and validated by sequencing. The assay was performed on 
DNA extracted from either whole blood using proteinase K digestion as described in Van 
Poucke et al.28 or from heart tissue as outlined above in 200 additional cats. These were 125 
Domestic Shorthairs and 25 cats each from the Ragdoll, Maine Coon and British Shorthair 
breeds. The resulting fragments were evaluated via gel electrophoresis. 
The sequences of the primer pairs and details on the (q)PCR, sequencing and assay reactions 
are given in Supplementary Tables 1-4. 
 
Results 
Clinical features 
The six year old Domestic Shorthair cat was presented to the university hospital with acute 
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paralysis of first one and then also the other pelvic leg. Three weeks previously, he had 
developed a cough that did not respond to antibiotics. The owner had noted no other clinical 
signs. The only information about family members that the owner could provide was that the 
only litter mate, a female, had been found dead suddenly at the age of two years. 
On inspection and physical examination the cat had tachypnoea, severe dyspnoea and 
cyanosis. Femoral pulses were absent and the hind legs were paralysed, cold and extremely 
painful when manipulated. Lung sounds were muffled ventrally and the dyspnoea made 
cardiac auscultation very difficult. The cat was hypothermic with a rectal temperature of 36 
ºC. 
Focused thoracic sonography showed multiple B-lines and focused cardiac sonography 
showed subjective thickening of the left ventricular free wall. The cat was diagnosed with 
thromboembolism of the distal aorta most likely due to hypertrophic cardiomyopathy, with a 
suspicion of pulmonary oedema. No further examinations were performed because of the poor 
general condition of the cat. Because of the severity of the clinical signs and the poor 
prognosis, the cat was euthanized.  
Pathological features 
Pathological examination revealed subjectively hypertrophic skeletal muscles and an enlarged 
heart that weighed 27.2 gram (normal weight: < 20 gram).29 The left ventricle felt firm on 
palpation and the left atrium was dilated. Transverse sectioning revealed concentric 
hypertrophy of the left ventricular wall with narrowing of the ventricular lumen. The 
thicknesses of the left ventricular free wall, interventricular septum and right ventricular free 
wall were 12, 9 and 3 mm, respectively. The lungs were congested and oedematous. 
Serohaemorrhagic fluid was present in the pleural cavity, trachea and nasal cavity. The 
kidneys showed multiple chronic infarctions. 
Histopathological examination of the left ventricle myocardium revealed a diffuse 
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hypertrophy and karyomegaly of the cardiomyocytes with multifocal areas of increased 
branching. There were also numerous small fibrotic septa intersecting the myocardium 
(interstitial fibrosis) with adjacent myofibre disarray. The subendocardial region of the left 
ventricle showed a non-circumferential extensive fibrosis with few scattered small areas of 
chondroid metaplasia and areas with large aggregates of hemosiderin-laden macrophages 
(iron-positive on Prussian blue). This thick subendocardial layer stained red on Von Giesson 
and blue on both Masson’s Trichrome and Alcian blue and showed a gradual increase in tissue 
density from luminal (loosely arranged collagen fibres) to myocardial (compact collagenous 
connective tissue). Immunohistochemistry for elastin revealed multifocal large areas of 
increased elastin deposition within the subendocardial layer.  The gross and histopathological 
lesions are consistent with a hypertrophic cardiomyopathy with areas of substantial 
subendocardial replacement fibrosis. Histopathological images of the heart are given in 
Supplementary Figures 1-5. 
Genetic analysis 
The qPCR assay was negative for both known MYBPC3 c.91G>C and c.2455C>T variants. 
By sequencing the coding region of the cDNA, seven silent and four missense variants in 
MYBPC3 and nine silent and one missense variant in MYH7 were found. They were all 
archived in the EVA database (https://www.ebi.ac.uk/eva/?Study-Browser&browserType=sgv; 
project ID: PRJEB30318; analysis ID: ERZ795310) and are listed in Supplementary Table 5.  
Only one variant, MYH7 c.5647G>A (p.(Glu1883Lys)), was found to change an amino acid 
that is highly conserved, both in its metazoan orthologues as in its feline and human 
paralogues, and predicted to be deleterious by PROVEAN (score: -2.613) and PolyPhen-2 
(HumDiv score: 1.000, HumVar score: 0.978). This variant was absent in the 200 additionally 
screened cats and its human orthologue was counted once in the 31 396 alleles in the 
GnomAD database and not found in the other human databases.  
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Discussion 
The physical examination abnormalities in this cat were highly suggestive of 
thromboembolism of the distal aorta. Most cases of feline arterial thromboembolism are 
caused by underlying cardiac disease, most commonly HCM.30 The respiratory signs were 
compatible with acute pain and with acute, severe congestive heart failure. The history of 
coughing might also be related to the heart disease, although cardiogenic coughing is rare in 
cats. 31 Ultrasound examination was limited by the critical condition of the patient, but was 
indicative for HCM.  
In cases of cardiomyopathy with severe fibrosis, there can be a thin line between HCM and 
restrictive cardiomyopathy, and there is evidence that the two conditions are different 
phenotypical expressions of the same genetic disease.32 Restrictive cardiomyopathy can also 
occur secondary to radiation fibrosis, nutritional deficiencies or infiltrative diseases such as 
amyloidosis, hypereosinophilia, sarcoidosis or endomyocarditis.33 In cats, it has also been 
suggested that it is the result of an end-stage HCM with myocardial failure or infarction.34 
Our case is compatible with a primary HCM because of the heart’s increased weight, size, 
wall thickness and firmness. It also displayed all histological features predominant for HCM 
such as cardiomyocytes displaying hypertrophy, karyomegaly, branching and myofibre 
disarray, admixed with myocardial interstitial fibrosis.35,36 The (sub)endocardial fibrosis was 
classified as a replacement fibrosis (secondary to ischemic infarction) as the histological 
features are consistent with chronic granulation/scar tissue and the presence of large 
aggregates of hemosiderin-laden macrophages is an indication of an old hemorrhage or 
infarct.The littermate’s history of sudden death is also compatible with HCM, although no 
necropsy had been performed to identify the cause of death in that cat.37 
Of the 21 variants that were found, only the five missense variants were further investigated, 
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as silent variants are not associated with HCM.2 The MYBPC3 c.772G>A (p.(Val258Ile)), 
c.2765C>T (p.(Pro922Leu)) and c.3109G>A (p.(Ala1037Thr)) variants were not considered 
to be causal, as the effects of the amino acid substitutions were predicted to be benign and 
each variant was found in the reference sequence of the mouse, rat, horse and at least one 
species of the Felidae family. The MYBPC3 c.220G>A (p.(Ala74Thr)) variant has been 
proposed earlier as a causative variant for HCM, but subsequent studies found that this variant 
is very common and not significantly associated with HCM.38 
This left only the MYH7 c.5647G>A variant as a possible causative variant, which has a 
human orthologue, NM_000257.3:c.5647G>A (p.(Glu1883Lys); rs121913652). This 
orthologue was described by Tajsharghi et al.39 in a consanguineous human family in which 
three of four siblings were diagnosed with both HCM and MSM as adults. Two patients died 
of heart failure and the coding regions of MYH7 in the third patient were sequenced. This 
patient was a homozygote for the variant, but its causality has been disputed because of 
limited evidence (see the discussion on ClinVar, variation ID: 14121). 
The human and feline cases had comparable HCM, but apparently different degrees of 
skeletal muscle disease. The human patients displayed a short stature, thoracic scoliosis, calf 
hypertrophy in one case and progressive muscle weakness.39 In contrast, the feline case had 
no musculoskeletal abnormalities other than the generalized muscle hypertrophy observed on 
necropsy. The owner had not observed muscle weakness. This comparative lack  of muscle 
disease might be explained by a species difference in muscle fibre types. As type I muscle 
fibres, that express MYH7, make up a larger proportion of muscles in large animals such as 
humans than in smaller cats8, a defect in MYH7 may have more severe consequences in 
humans. The muscular hypertrophy observed in this cat might have compensated the defect to 
an extent that allowed normal locomotor function. However, it is also possible that some 
degree of muscle weakness was present, but not recognized, as even severe myopathy in cats 
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can go unnoticed by the owner and veterinarian.40,41 Histopathology of skeletal muscles was 
not available to compare to the MSM phenotype in humans. 
The human patient carrying the  MYH7 c.5647G>A variant was a homozygote and Tajsharghi 
et al. suggested an autosomal recessive pattern of inheritance for this variant.39 However, both 
HCM and MSM generally show an autosomal dominant pattern of inheritance and this might 
also have been the case in this human family.2,9 The two affected siblings that were not 
genotyped could be heterozygotes and it is not clear whether cardiomyopathy was ruled out in 
the parents, especially the father who died of stroke at age 58.39 The cat described here was a 
heterozygote, consistent with an autosomal dominant pattern of inheritance. Because of the 
suspicion of HCM in the litter mate, it is considered unlikely that the causative variant was a 
de novo variant. The MYH7 c.5647G>A variant is extremely rare in humans and the absence 
of this variant in the 200 additional cats suggests that it is also rare in cats. 
The affected glutamic acid residue is part of the assembly competence domain (ACD), a C-
terminal 29 amino acid region that has a distinct pattern of four negative charges surrounded 
by positive charges and is essential for sarcomeric thick filament assembly.42 During the 
assembly process, the tails of myosin heavy chains form coiled coils, the coils dimerize tail-
to-tail and then aggregate into filaments.43 The tail-to-tail dimerization requires the correct 
functioning of the ACD, which is highly conserved in myosin-7 orthologues across species as 
well as in the striated muscle myosin heavy chain paralogues of cats and humans (Figure 
1).42,43  
The p.(Glu1883Lys) variant substitutes one of the four negative charges by a positive charge. 
In vitro assessment of this substitution shows a lower stability and higher solubility of the 
protein, indicating a reduced assembling capacity.44 For a similar substitution (Glu1886Lys), 
it was shown that the extent of filament assembly is reduced to 60% compared to the wild 
type.45 Expression of Glu1883Lys mutant protein in a Drosophila animal model causes 
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ultrastructural thick filament misalignment and disrupted sarcomere structure in pupae. In 
adults, these abnormalities worsen and are complemented with hyaline bodies reminiscent of 
human MSM. These adults show a compromised ability to fly and jump, indicating severe 
functional effects of this variant, as predicted by computational and predictive data.44 
In addition, a paralogous variant in MYH6, the major myosin heavy chain gene expressed in 
the cardiac atria7, causes an identical charge pattern disruption of the ACD with deleterious 
phenotypical effects in humans. This variant, NM_002471.3:c.5653G>A (p.(Glu1885Lys); 
rs760353963), is considered to be the causative variant in a family where Wolff-Parkinson-
White syndrome segregates in an autosomal dominant pattern with incomplete penetrance.46 It 
is also considered to have contributed to lethal congenital heart disease in a compound 
heterozygote who also carried another MYH6 variant.47 
By adding the data of the orthologous feline case to that of the already described human 
family, together with the updated population data, the recently described functional studies 
and the paralogous human MYH6 variant, there is now enough evidence to classify the 
NM_000257.3:c.5647G>A (p.(Glu1883Lys)) variant as HCM-causing, according to the 
standards and guidelines for the interpretation of sequence variants.48 
This is the first report of HCM caused by a variant in MYH7 in a cat. An earlier study 
sequencing sarcomeric candidate genes, including MYH7, in 14 HCM-affected cats did not 
identify any disease-causing variant.49 A recent, more extensive study identified several 
candidate variants, but not in MYH7.50 It might be interesting to investigate if this variant is 
also the causal variant in other Domestic Shorthair HCM cases. 
Variants that cause HCM in humans are generally rare and the clinical significance of a 
variant found in human patients is not always clear.1,2 The identification of an orthologous 
variant in a spontaneous animal model of HCM can support its causality in humans. The 
involvement of MYH7, in addition to MYBPC3, in feline HCM suggests that its similarity to 
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human HCM extends to the genetic level. As most cases of feline HCM are idiopathic, further 
investigations on its aetiology are needed to confirm this genetic similarity. In addition to the 
phenotypic similarity, this similarity would make cats with HCM a suitable animal model for 
the development of preventive and therapeutic strategies for HCM. 
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Figure 1 Position and evolutionary conservation of the ACD. 
 
A. Tail-to-tail dimerization of the coiled coils formed by myosin heavy chains. The ACD 
regions are shaded light-grey. B. The amino acid sequence and charge pattern of the ACD in 
myosin-7 (myosin heavy chain for Drosophila) orthologues across species (1) and skeletal 
and cardiac muscle myosin heavy chain paralogues in humans (2). Accession numbers are 
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given in parentheses and identical amino acids are depicted as “.”. The variants cause the 
substitution of a conserved, negatively charged glutamic acid residue by a positively charged 
lysine residue. C. Chromatograms of a homozygous wild type cat (1) and the heterozygous 
case (2). The variant changes codon 1883 from GAG to AAG. D. Agarose gel electrophoresis 
of an uncleaved amplicon (1), 376 bp long, the cleaved amplicons of a homozygous wild type 
cat (2) and the heterozygote case (3) and a negative control (4). The amplicon is always 
cleaved at an internal cleavage site in a large fragment of 335 bp and a small fragment of 41 
bp. The wild type large fragment contains a second recognition site and is cleaved in 
fragments of 187 and 148 bp, while the variant large fragment does not contain a recognition 
site and remains intact. Two percent agarose gel with Hyperladder V. 
